Merck gets on the Treg train with Pandion buy
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
Glaxo fails to win an Oscar
There might be a use for Glaxo’s anti-Covid-19 antibody otilimab in old patients, but repeating Actemra’s trick will not be easy.
Vaccine developers move to stay ahead of Covid-19 variants
Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.
Comirnaty is the real deal in the real world
Data from Israel’s real-world experience with Pfizer/Biontech’s Covid-19 vaccine should silence any doubters.
J&J’s Covid-19 vaccine set to become third to US
FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
